METHOD FOR PERFORMING EARLY DIAGNOSIS OF SEPSIS USING ANALYSIS DEVICE INCLUDING MICRO FILTER

IMPROVED METHODS AND DEVICES FOR ACCURATE DIAGNOSIS OF INFECTIONS

PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS

ANTIBIOTIC THERAPY GUIDANCE BASED ON PROCALCITONIN IN PATIENTS WITH COMORBIDITIES

DEVICES AND METHODS FOR DIAGNOSISING THYROID MEDICAL CONDITIONS

DETECTION METHOD USING BOTH FLUORESCENCE AND CHEMILUMINESCENCE LABELS

PCT MARKER PANELS FOR EARLY DETECTION OF SEPSIS

METHOD AND KIT OF MEASURING CONCENTRATION OF ANALYTE

Treatment of severe community acquired pneumonia

DETECTING SEPSIS

METHODS FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN THE PLASMA FRACTION OF A SAMPLE OF WHOLE BLOOD

DIAGNOSTIC REAGENT FOR QUANTITATIVE DETERMINATION OF PROCALCITONIN IN A SAMPLE

Medical devices and methods thereof for determining bacterial infections in blood

Protein signatures for distinguishing between bacterial and viral infections

Biomarkers for the diagnosis of invasive fungal infections

SIMULTANEOUS DETECTION OF HUMORAL AND INFLAMMATORY BIOMARKERS

System and Method for Disease Surveillance and Disease Severity Monitoring for COVID-19

Methods of prognosis and treatment

Treatment of severe community acquired pneumonia

ANTIBIOTIC THERAPY GUIDANCE BASED ON PRO-ADM

Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin

METHODS AND DEVICES FOR ACCURATE DIAGNOSIS OF INFECTIONS

Antibiotic therapy guidance based on procalcitonin in patients with comorbidities

Treatment of severe community acquired pneumonia

System and method for detection of trauma

Biomarker detection system

Procalcitonin for the prognosis of adverse events

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

DETECTING SEPSIS

Protein signatures for distinguishing between bacterial and viral infections

CGRP ANTIBODIES AND USES THEREOF

Monoclonal antibody of human-derived procalcitonin, and preparation method and application thereof

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

Biochemical-immunological hybrid biosensor and sensor system including the same

RISK ASSESSMENT FOR ANTIBIOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN

Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints

PROGNOSIS OF ADVERSE EVENTS IN PATIENTS WITH SUSPECTED CHRONIC HEART FAILURE

NUCLEIC ACID APTAMER-BASED DIAGNOSTIC METHODS WITH NOVEL TECHNIQUES FOR SIGNAL ENHANCEMENT

Methods and devices for accurate diagnosis of infections

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

Prognosis of adverse events in patients with suspected chronic heart failure

Marker of cell death

Method for risk stratification in stable coronary artery disease

Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid

Pre-eclampsia biomarkers

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

Use of interleukin-27 as a diagnostic biomarker for bacterial infection in critically ill patients

Nucleic acid aptamer-based diagnostic methods with novel techniques for signal enhancement

Low Volume Assay Device Having Increased Sensitivity

Method for risk stratification in stable coronary artery disease

PREDICTION OF OUTCOME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Prognosis of adverse events in patients with suspected chronic heart failure

Prognosis and risk assessment in stroke patients by determining the level of marker peptides

Procalcitonin gene expression as a precise biomarker of aging process

Method for the selective detection and measurement of procalcitonin 1-116 and amino-terminal peptides of procalcitonin comprising amino acids 1 and 2 of procalcitonin 1-116

METHOD FOR PREDICTING HIGH-GRADE VESICOURETERAL REFLUX IN CHILDREN WITH A FIRST FEBRILE URINARY TRACT INFECTION

PROCALCITONIN FOR THE PROGNOSIS OF ADVERSE EVENTS

Method for risk stratification in stable coronary artery disease

IMMUNOASSAY FOR THE DETECTION OF PROCALCITONIN

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES

Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin

Methods of treating cancer using the calcitonin-gene related peptide (“CGRP”) receptor antagonist CGRP8-37

Marker for graft failure and mortality

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

USE OF PROCALCITONIN (PCT) IN RISK STRATIFICATION AND PROGNOSIS OF PATIENTS WITH A PRIMARY, NON-INFECTIOUS DISEASE

Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack

Diagnosis and treatment of diseased and damaged tissue

Method for the detection of sepsis by determining peptide prohormone levels

IN VITRO METHOD FOR DIAGNOSING TUMOR DISEASES

Antibodies for the selective determination of procalcitonin 1-116

Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure

Method for the detection of sepsis using procalcitonin-3-116

Method for determining sepsis using pro-ADM

Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma

Method for determining sepsis using pro-BNP

Csf Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases

Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes